Cliff Richard Reveals Year-Long Prostate Cancer Battle, Advocates for Screening

Singer Cliff Richard, aged 85, has disclosed that he underwent treatment for prostate cancer over the past year. In a candid interview with Good Morning Britain, Richard shared that while his cancer is currently in remission, he is advocating for national screening tests for men. “I don’t know whether it’s going to come back. We can’t tell those sort of things but we need to – absolutely. I’m convinced: get there, get tested, get checked,” he stated.

Richard’s diagnosis came following a health check related to insurance prior to his concert tour in Australia and New Zealand. He expressed gratitude that the cancer was detected early and did not spread to other parts of his body. “The good fortune was that it was not very old; and the other thing is that it has not metastasised. Nothing had moved into bones or anything like that,” he explained.

Advocating for National Screening

During the interview, Richard criticized the absence of a national prostate cancer screening programme in the UK, calling it “absolutely ridiculous.” He emphasized the responsibility of governments to ensure that all citizens have access to necessary health screenings. “We all deserve to have the same ability to have a test and then start treatments really early,” he stressed.

Richard’s comments come as discussions about prostate cancer awareness gain momentum. Last week, King Charles announced plans to reduce his own cancer treatment in the new year. Richard expressed a desire to collaborate with the King to raise awareness about prostate cancer. “I’ve been involved with many charities over the years, and if the king is happy to front it for us, I’m sure loads of people – I certainly would join him,” he said.

In November, the UK National Screening Committee revealed a draft recommendation for a targeted prostate cancer screening programme. If approved, this initiative would invite men aged between 45 and 61 who carry genetic mutations of the BRCA1 or BRCA2 genes to participate in screenings every two years. This potential programme underscores the importance of early detection and treatment of prostate cancer, a sentiment echoed by Richard throughout his advocacy.

His journey with cancer has highlighted the urgent need for improved health resources and public awareness regarding prostate cancer. As Richard continues to share his experience, he hopes to inspire others to prioritize their health and consider regular screenings.